New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
12:35 EDTGAME, CRZBY, XRX, MRK, DB, RHI, CAT, CRARY, GERNOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday as a decline in new home sales last month more than offset any positive momentum built in the early hours by Caterpillar's (CAT) better than expected earning report. Stocks began the week in positive territory, briefly bouncing back from last week’s sell-off, but the market resumed its downward trend by the time the larger than expected drop in new home sales was reported near 10 am ET. As the lunch hour approached, the averages were all in the red and stood near session lows. ECONOMIC EVENTS: In the U.S., new home sales dropped 7% to a 414K rate in December from a downwardly revised 445K rate in November, missing expectations. However, the report may have been somewhat discounted as largely due to the extreme weather seen in many markets during the month. In Europe, the Ifo institute’s German business confidence measure beat economists’ forecasts and rose to its highest level in more than two years with a 110.6 reading in January. Also, the Organization for Economic Cooperation and Development reportedly estimated that European banks have a combined capital shortfall of about 84 billion euros, with Credit Agricole (CRARY), Deutsche Bank (DB) and Commerzbank (CRZBY) listed among the banks having significant gaps. COMPANY NEWS: Dow component Caterpillar advanced about 4% after its quarterly earnings easily beat the consensus expectation of analysts. The company also gave a forecast for revenue in the new fiscal year that surpassed expectations and approved a program to repurchase up to $10B of its shares. MAJOR MOVERS: Among the notable gainers was Chinese online game maker Shanda Games (GAME), which gained 13% after its controlling shareholder proposed to acquire the company in a "going private" transaction for $6.90 per American depositary share. Also higher was Robert Half (RHI), which rose 3% following an upgrade to Buy from Neutral at research firm Northcoast, which cited the valuation of its shares and expectations for top-line trends to accelerate due to easier comparisons and improving end markets. Also higher following an upgrade were shares of Merck (MRK), which gained nearly 3% after Morgan Stanley upgraded the stock two notches to Overweight from Underweight. Among the noteworthy losers was Geron (GERN), which fell 19% after disclosing that an investigator-sponsored clinical trial to evaluate imetelstat in patients with myelofibrosis and other myeloid malignancies has been closed to new patient enrollment and that the company believes approximately 20 patients have discontinued from the study since its inception. Also lower were shares of Xerox (XRX), which were downgraded to Market Perform from Outperform at BMO Capital and slid almost 5% near noon. INDEXES: Near midday, the Dow was down 76.11, or 0.48%, to 15,803.00, the Nasdaq was down 69.13, or 1.67%, to 4,059.04, and the S&P 500 was down 15.10, or 0.84%, to 1,775.19.
News For CAT;MRK;GAME;RHI;XRX;GERN;DB;CRZBY;CRARY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 15, 2015
06:20 EDTDBDeutsche Bank fined $8.4M by Dubai Financial Services Authority
Subscribe for More Information
April 14, 2015
13:32 EDTMRKMerck, NewLink Genetics confirm initiation of Phase 3 trial of Ebola vaccine
Subscribe for More Information
April 13, 2015
20:02 EDTDBDeutsche Bank to reach decision on future business model next week, Reuters says
Deutsche Bank's management board will reach a decision on the company's future business model by next week and present its plans during an April 24 extraordinary supervisory board meeting, reports Reuters, citing the newspaper Handelsblatt. The strategy could be made public April 29, said the report. Reference Link
14:44 EDTDBDeutsche Bank decision on business model due next week, Reuters says
Subscribe for More Information
08:58 EDTMRKMerck may have positive read through from briefing docs, says SunTrust
Subscribe for More Information
April 10, 2015
11:01 EDTCATCaterpillar announces new Analytics & Innovation division
To better capitalize on the growing importance and excitement of data analytics and to drive innovation to support customers, Caterpillar announced the formation of a new division, Analytics & Innovation, which will be led by Caterpillar Vice President Greg Folley. The division will bring together the people and resources that will foster a culture with innovation at the core, form a broad and connected analytics ecosystem and manage strategic third party relationships with providers like Chicago, Illinois-based Uptake, a start-up with which the company recently announced a technology and predictive analytics agreement. Caterpillar will co-locate key employees with the Uptake team in Chicago to accelerate the work needed to create a platform that takes massive amounts of data, combines it with data science to understand patterns and quickly deploys information to save customers money, optimize performance and prevent unplanned downtime. The company is also placing resources in the Silicon Valley and has seeded money in a venture capital fund with the goal of investing in emerging technologies that could further enhance Caterpillar's product and service development. All of these activities under the umbrella of the AI division will complement the innovative work that thousands of Caterpillar employees are already doing around the world— a trait that has been critical to Caterpillar's success since the formation of the company 90 years ago.
April 9, 2015
16:58 EDTDBDeutsche Bank close to deal in LIBOR case, NYT reports
Subscribe for More Information
16:54 EDTDBDeutsche Bank close to deal in LIBOR case, NYT reports
Subscribe for More Information
09:25 EDTMRKPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
April 8, 2015
15:38 EDTCATCaterpillar nominates Sempra Energy CEO to board
Subscribe for More Information
10:01 EDTXRXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:33 EDTMRKAdvaxis, Merck begin enrollment in Phase 1/2 of ADJX-PSA with Keytruda
Advaxis (ADXS) and Merck (MRK) announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA, an investigational Lm-LLO immunotherapy, and Keytruda, the first anti-PD-1 therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer, or mCRPC. The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer. ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination.
07:04 EDTMRKMerck's investigational Hep C therapy granted breakthrough therapy designations
Subscribe for More Information
April 7, 2015
16:55 EDTXRXXerox upgraded to Buy ahead of Q1 results at Citigroup
Subscribe for More Information
16:06 EDTXRXXerox upgraded to Buy from Neutral at Citigroup
Subscribe for More Information
07:14 EDTMRKEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
April 6, 2015
16:31 EDTDBDeutsche Bank begins talks to sell Plenary Group stake, AFR says
Subscribe for More Information
06:23 EDTCRZBYJudge approves Commerzbank, U.S. settlement, Reuters reports
Subscribe for More Information
April 5, 2015
12:41 EDTGAMEShanda Games in merger agreement for 'going private' transaction
Subscribe for More Information
08:43 EDTCATAT&T, Philip Morris, eight others have reliable yields up to 5.7%, Barron's says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use